This is a StreetInsider.com Premium Only Page

Cara Therapeutics (CARA) – Business Wire

Aug 19, 2022 01:00 AM Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

Apr 28, 2022 01:00 AM Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

Feb 28, 2022 01:00 AM Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

Aug 24, 2021 01:00 AM Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

Mar 30, 2021 01:00 AM VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin

Mar 8, 2021 01:00 AM Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus

Dec 16, 2020 07:27 AM SAB Biotherapeutics Announces New Appointments to its Board of Directors

Oct 20, 2020 01:00 AM Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus

Apr 21, 2020 01:30 AM VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus